| No. (%) |
---|---|
Age, median, years | 54 (43–63) |
 ≤65 | 84 (84.0%) |
 > 65 | 16 (16.0%) |
Sex | |
 Male | 73 (73.0%) |
 Female | 27 (27.0%) |
KPS | |
 90 | 78 (78.0%) |
 80 | 22 (22.0%) |
BMI, median, | 21.4 (19.5–23.6) |
Primary tumor length, median, cm | 7.4 (1.7–8.9) |
Primary tumor location | |
 Sigmoid colon | 60 (60.0%) |
 Descending colon | 3 (3.0%) |
 Transverse colon | 10 (10.0%) |
 Ascending colon | 25 (25.0%) |
 Ileocecus | 2 (2.0%) |
Tumor differentiation | |
 High | 20 (20.0%) |
 Moderate | 65 (65.0%) |
 Low | 15 (15.0%) |
CEA pre-CRT, median, ng/ml | 6.1 (3.0–21.3) |
Complication | |
 No | 56 (56.0%) |
 Yes | 44 (44.0%) |
cT stage | |
 T3 | 4 (4.0%) |
 T4a | 12 (12.0%) |
 T4b | 84 (84.0%) |
cN stage | |
 N0 | 1 (1.0%) |
 N1 | 36 (36.0%) |
 N2 | 63 (63.0%) |
Clinical stage | |
 IIC | 1 (1.0%) |
 IIIB | 16 (16.0%) |
 IIIC | 83 (83.0%) |
Involved organ | |
 Bladder | 42 (42.0%) |
 Ureter | 12 (12.0%) |
 Renal and perirenal fat, prerenal space | 6 (6.0%) |
 Pelvic wall | 10 (10.0%) |
 Presacral space | 2 (2.0%) |
 Abdominal wall | 11 (11.0%) |
 Mesentery | 2 (2.0%) |
 Great vessel | 8 (8.0%) |
 Small intestine | 26 (26.0%) |
 Greater omentum | 5 (5.0%) |
 Gallbladder | 6 (6.0%) |
 Liver | 9 (9.0%) |
 Appendix | 1 (1.0%) |
 Pancreas | 2 (2.0%) |
 Uterus | 6 (6.0%) |
 Vagina | 1 (1.0%) |
 Seminal vesicle gland | 3 (3.0%) |
 Vas deferens | 2 (2.0%) |
 Iliopsoas muscle | 1 (1.0%) |
Bladder fistula/perforation | |
 Yes | 14 (14.0%) |
 No | 86 (86.0%) |
Intestinal obstruction | |
 Yes | 19 (19.0%) |
 No | 81 (81.0%) |
Family history | |
 Yes | 20 (20.0%) |
 No | 80 (80.0%) |
Charlson Comorbidity Score | |
 0 | 82 (82.0%) |
 1 | 15 (15.0%) |
 2 | 2 (2.0%) |
 3 | 1 (1.0%) |
MMR | |
 dMMR | 14 (22.6%) |
 pMMR | 48 (77.4%) |
 Unknown | 38 |